Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 2836 | 2.36 |
09:34 ET | 580 | 2.36 |
09:36 ET | 5840 | 2.3699 |
09:38 ET | 8323 | 2.38 |
09:39 ET | 300 | 2.385 |
09:41 ET | 306 | 2.38 |
09:43 ET | 1100 | 2.38 |
09:45 ET | 807 | 2.37 |
09:48 ET | 2998 | 2.375 |
09:50 ET | 1600 | 2.38 |
09:52 ET | 500 | 2.388 |
09:54 ET | 100 | 2.38 |
09:56 ET | 2500 | 2.375 |
09:57 ET | 644 | 2.36 |
10:01 ET | 2467 | 2.37 |
10:03 ET | 1271 | 2.37 |
10:06 ET | 100 | 2.36 |
10:08 ET | 701 | 2.36 |
10:10 ET | 2372 | 2.355 |
10:12 ET | 355 | 2.3501 |
10:14 ET | 11763 | 2.325 |
10:15 ET | 14729 | 2.3208 |
10:17 ET | 2802 | 2.325 |
10:19 ET | 4913 | 2.325 |
10:21 ET | 19623 | 2.3108 |
10:24 ET | 10773 | 2.325 |
10:26 ET | 29727 | 2.365 |
10:28 ET | 11125 | 2.355 |
10:30 ET | 800 | 2.35 |
10:32 ET | 6700 | 2.355 |
10:33 ET | 200 | 2.3575 |
10:35 ET | 266 | 2.35 |
10:37 ET | 1212 | 2.355 |
10:39 ET | 7049 | 2.355 |
10:42 ET | 6926 | 2.3509 |
10:44 ET | 1600 | 2.355 |
10:46 ET | 10879 | 2.365 |
10:48 ET | 482 | 2.365 |
10:50 ET | 11331 | 2.3523 |
10:51 ET | 100 | 2.35 |
10:55 ET | 599 | 2.355 |
10:57 ET | 300 | 2.35 |
11:00 ET | 211 | 2.3591 |
11:02 ET | 1669 | 2.355 |
11:04 ET | 100 | 2.3591 |
11:06 ET | 1815 | 2.35 |
11:08 ET | 2976 | 2.35 |
11:11 ET | 2156 | 2.365 |
11:13 ET | 200 | 2.36 |
11:15 ET | 10049 | 2.3499 |
11:18 ET | 14383 | 2.35 |
11:20 ET | 8505 | 2.35 |
11:22 ET | 5778 | 2.355 |
11:24 ET | 900 | 2.355 |
11:26 ET | 361 | 2.3509 |
11:27 ET | 2650 | 2.36 |
11:29 ET | 300 | 2.3591 |
11:31 ET | 8607 | 2.3699 |
11:33 ET | 214 | 2.379 |
11:36 ET | 6767 | 2.37 |
11:38 ET | 922 | 2.37 |
11:40 ET | 1149 | 2.3601 |
11:42 ET | 6601 | 2.3675 |
11:44 ET | 3855 | 2.365 |
11:45 ET | 200 | 2.365 |
11:49 ET | 11009 | 2.3701 |
11:51 ET | 2045 | 2.37 |
11:54 ET | 797 | 2.369 |
11:56 ET | 1664 | 2.36 |
12:00 ET | 492 | 2.365 |
12:02 ET | 984 | 2.36 |
12:03 ET | 200 | 2.36 |
12:05 ET | 4452 | 2.35 |
12:07 ET | 368 | 2.35 |
12:09 ET | 1740 | 2.349 |
12:12 ET | 3087 | 2.34 |
12:14 ET | 400 | 2.3491 |
12:16 ET | 4170 | 2.3399 |
12:18 ET | 33978 | 2.31 |
12:20 ET | 4172 | 2.305 |
12:21 ET | 76933 | 2.3 |
12:23 ET | 4330 | 2.3091 |
12:25 ET | 7101 | 2.295 |
12:27 ET | 7590 | 2.31 |
12:30 ET | 722 | 2.315 |
12:32 ET | 1271 | 2.32 |
12:34 ET | 1149 | 2.32 |
12:36 ET | 241 | 2.325 |
12:38 ET | 1000 | 2.33 |
12:39 ET | 200 | 2.325 |
12:41 ET | 100 | 2.33 |
12:45 ET | 632 | 2.32 |
12:48 ET | 4257 | 2.3199 |
12:50 ET | 1229 | 2.31 |
12:52 ET | 2194 | 2.32 |
12:54 ET | 400 | 2.325 |
12:56 ET | 450 | 2.325 |
12:59 ET | 100 | 2.32 |
01:01 ET | 200 | 2.32 |
01:03 ET | 468 | 2.32 |
01:08 ET | 566 | 2.325 |
01:10 ET | 1301 | 2.31 |
01:14 ET | 529 | 2.31 |
01:15 ET | 100 | 2.315 |
01:17 ET | 4600 | 2.315 |
01:19 ET | 6346 | 2.305 |
01:21 ET | 1700 | 2.305 |
01:24 ET | 13981 | 2.321 |
01:26 ET | 800 | 2.325 |
01:28 ET | 900 | 2.325 |
01:30 ET | 4850 | 2.33 |
01:32 ET | 5825 | 2.345 |
01:33 ET | 3000 | 2.34 |
01:35 ET | 20362 | 2.335 |
01:37 ET | 4316 | 2.32 |
01:39 ET | 700 | 2.315 |
01:42 ET | 900 | 2.315 |
01:44 ET | 4069 | 2.32 |
01:46 ET | 2100 | 2.32 |
01:48 ET | 9300 | 2.32 |
01:50 ET | 1036 | 2.325 |
01:51 ET | 3400 | 2.325 |
01:53 ET | 4200 | 2.325 |
01:55 ET | 4137 | 2.3212 |
01:57 ET | 917 | 2.33 |
02:00 ET | 36369 | 2.35 |
02:02 ET | 31483 | 2.355 |
02:04 ET | 7744 | 2.355 |
02:06 ET | 100 | 2.36 |
02:08 ET | 950 | 2.355 |
02:09 ET | 949 | 2.359 |
02:11 ET | 14600 | 2.355 |
02:13 ET | 5900 | 2.355 |
02:15 ET | 1800 | 2.355 |
02:18 ET | 5400 | 2.355 |
02:20 ET | 8085 | 2.335 |
02:22 ET | 922 | 2.335 |
02:24 ET | 866 | 2.345 |
02:26 ET | 700 | 2.345 |
02:27 ET | 1090 | 2.35 |
02:29 ET | 13352 | 2.33 |
02:31 ET | 2000 | 2.33 |
02:33 ET | 1184 | 2.33 |
02:36 ET | 100 | 2.325 |
02:38 ET | 500 | 2.325 |
02:40 ET | 700 | 2.3299 |
02:42 ET | 1000 | 2.3269 |
02:45 ET | 21418 | 2.34 |
02:47 ET | 1000 | 2.34 |
02:49 ET | 400 | 2.335 |
02:51 ET | 100 | 2.335 |
02:54 ET | 2900 | 2.325 |
02:56 ET | 3014 | 2.325 |
02:58 ET | 238 | 2.325 |
03:00 ET | 646 | 2.325 |
03:02 ET | 122 | 2.32 |
03:03 ET | 993 | 2.32 |
03:05 ET | 600 | 2.32 |
03:07 ET | 644 | 2.325 |
03:09 ET | 1600 | 2.32 |
03:12 ET | 625 | 2.325 |
03:14 ET | 2139 | 2.32 |
03:16 ET | 600 | 2.325 |
03:18 ET | 763 | 2.32 |
03:20 ET | 537 | 2.325 |
03:23 ET | 497 | 2.325 |
03:25 ET | 13296 | 2.325 |
03:27 ET | 446 | 2.325 |
03:30 ET | 2392 | 2.335 |
03:32 ET | 400 | 2.335 |
03:34 ET | 2480 | 2.32 |
03:36 ET | 1400 | 2.315 |
03:38 ET | 2331 | 2.315 |
03:39 ET | 297 | 2.315 |
03:41 ET | 2419 | 2.315 |
03:43 ET | 880 | 2.315 |
03:45 ET | 1690 | 2.315 |
03:48 ET | 1774 | 2.315 |
03:50 ET | 2300 | 2.315 |
03:52 ET | 4927 | 2.31 |
03:54 ET | 19126 | 2.315 |
03:56 ET | 25521 | 2.31 |
03:57 ET | 25574 | 2.311 |
03:59 ET | 157625 | 2.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 166.8M | -0.8x | --- |
Galectin Therapeutics Inc | 165.0M | -3.5x | --- |
Tenaya Therapeutics Inc | 159.4M | -1.3x | --- |
Atossa Therapeutics Inc | 174.8M | -7.3x | --- |
Achieve Life Sciences Inc | 152.5M | -4.3x | --- |
DiaMedica Therapeutics Inc | 183.8M | -8.0x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $166.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.79 |
Book Value | $4.12 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.